

Index

- 45 and Up Study, 104
- absolute risk increase (ARI), 132–3
- absolute risk reduction (ARR), 132–3
- accuracy
- assessing in measurement, 179
 - cause of death, 75
 - diagnostic tests, 336
 - of measurements, 172
 - screening tests, 329
 - see also* precision
- active surveillance, 268
- acute laryngitis, and antibiotics, 246
- administrative health systems, 68
- adult mortality rates, 51
- age
- and body mass index (BMI), 146, 148
 - distributions, 50
- age-specific rates, 43–4
- age-standardised rates, 45–6, 50
- agents of infection, *see* infectious agents
- air pollution, and asthma, 149
- airborne transmission, 289
- alcohol, and lung cancer, 187–9, 190
- alpha (α) errors, 147
- alternative hypothesis, 147
- American Institute of Cancer Research, 260
- analogy, in evaluating causation, 241
- analytic studies, 21, 93, 161, 173
- antibiotics, and acute laryngitis, 246
- ascertainment bias, 166
- aspirin
- and colorectal cancer, 238
 - and endocarditis, 40, 124
- associations
- aspects to consider, 238–42
 - between outcomes and exposure, 147
 - and chance, 147–8
 - in clinical epidemiology, 129
 - confounding, 192, 194
 - continuous measures, 139
 - looking for, 121–2
 - missed true, 151–3
 - strength of, 123, 151, 238
 - versus causation, 233–5
 - see also* measures of association
- asthma
- and air pollution, 149
 - and body mass index (BMI), 216–17
 - and smoking, 32
- atrial fibrillation, and statin use, 219
- attack rates, 4, 36, 287
- see also* incidence proportion (IP)
- attributable burden of disease, 315
- attributable fractions (AF), 131–2, 136–7, 315
- see also* population attributable fractions (PAF)
- attributable proportion, *see* attributable fractions (AF)
- attributable risk percent, *see* attributable fractions (AF)
- attributable risks (AR)
- calculation, 131, 132
 - caution regarding, 138
 - clinical epidemiology, 132
 - interpreting, 132–3
 - measures, 129–38
 - population, 133–4
 - strengths and uses, 139
 - versus relative risks, 138–9
- Australian National Health Survey, 80
- Australian Ovarian Cancer Study, 107
- autism spectrum disorders, and flea treatment, 217
- autonomy and ethics, 113
- autopsies, verbal, 72
- Avon Longitudinal Study of Parents and Children (UK), 103
- background rates, 130
- background risks, 130
- Beecher's Report, 114
- Behavioral Risk Factor Surveillance System (BRFSS), 274
- Belmont Report, 114
- beneficence, 113
- Berkson's bias, 166
- β -carotene, 355–6
- beta (β) errors, 147, 151–2
- bias
- when evaluating screening programs, 341–5
 - with hospital controls, 108
 - interviewer or observer, 110, 178
 - and misclassification, 173
 - see also* specific types e.g. selection bias
- bicycle helmets, and head injury, 137, 207
- big data, 86–7
- bioaerosols, 289
- biological plausibility, 240
- BIOSIS database, 247
- birth defects, and thalidomide, 107
- birthweight, and breast cancer, 254–5
- blinding, 97
- blood pressure, and cardiovascular disease, 309–10, 312
- blood transfusion, and Creutzfeldt–Jakob disease (CJD), 214
- body mass index (BMI)
- and age, 146, 148
 - and asthma, 216–17
 - and diabetes, 313
 - and type-2 diabetes, 239–40
- brain cancer, and mobile telephones, 254–5
- breast cancer
- and birthweight, 254–5
 - cases at Toowong ABC, 298
 - control of, 305, 306
 - screening for, 261, 330, 341–2, 343, 348
- British Doctors Study, 15, 21, 102, 103, 138–9
- burden of disease, 135, 267, 305, 314–16
- Canadian Task Force on Preventive Health Care (CTFPHC), 250
- cancer
- disease registries, 75
 - standardised mortality ratios (SMR), 84
 - see also* specific types e.g. breast cancer
- cancer epidemiology, 4
- cardiovascular disease (CVD)
- and blood pressure, 309–10, 312
 - and disability-adjusted life years (DALYs), 233–2
 - mortality rates, 319
 - risk factors, 307–8

- cardiovascular disease (CVD) (cont.)
 - standardised mortality ratios (SMR), 84
 - terms used, 45
 - see also* ischaemic heart disease (IHD)
- case-cohort studies, 105
- case-control studies, 106–10
 - attributable fractions (AF), 136–7
 - and confounding, 187–9
 - control selection, 108
 - detection bias, 166
 - eligibility and exclusion criteria, 168
 - estimating incidence, 126
 - and hospital controls, 108–9
 - interviewer or observer bias, 110
 - low response rates, 163–4
 - matching, 198, 199
 - measurement errors, 173, 181
 - nested, 105, 106
 - odds ratios, 126–7
 - recall bias, 110
 - and screening programs, 347
 - selection bias, 161, 169
- case-crossover studies, 110
- case definitions, 29, 276, 292
- case fatality ratio (CFR), 50, 61
- case-finding, 327
- case-reference (or case-referent) studies, *see* case-control studies
- case reports, 67
- case series, 67
- categorical data, 139
- causal diagrams, *see* directed acyclic graphs (DAGs)
- causal model for infectious diseases, 287
- causal reasoning, 235
- causation, 230
 - considering, 232
 - counterfactual (potential) outcomes model of, 236–7
 - definition, 230–1
 - evaluating, 235, 236, 238–42
 - evidence for outbreaks, 295–6
 - identifying, 16
 - models of, 231–2, 237
 - versus association, 233–5
- cause of death
 - accuracy, 72, 75
 - coding, 70, 72, 73, 75
- census data, 68
- Centers for Disease Control and Prevention (CDC), 291
- cervical cancer, 346–7, 360
- chance, 147–8, 220
- chicken pox, 270
- child mortality rates, 51
- cholera, 12–14, 22–4, 233–5
- cholesterol levels, and ischaemic heart disease (IHD), 310
- ciguatera, 298
- civil registration systems, 68, 70–1
- clinical epidemiology, 5, 124, 128–9, 132
- clinical significance, 155–6
 - versus statistical significance, 155–6
- clinical trials, 40, 95, 162
 - see also* randomised controlled trials (RCTs)
- cluster randomised controlled trials, 99
- clusters
 - definition, 284
 - historical, 297
 - investigation of, 297–8
 - non-infectious diseases, 296–9
 - and surveillance, 267
 - see also* outbreaks
- Cochrane Central Register of Controlled Trials, 247
- Cochrane Collaboration, 219, 256, 360
- coherence, in evaluating causation, 241
- cohort studies, 100–3
 - case-cohort studies, 105
 - compared to randomised controlled trials, 101
 - and confounding, 192
 - definition, 36
 - historical, 103
 - loss to follow-up, 162, 166, 170
 - matching, 198
 - measurement errors, 173
 - notable examples, 101, 103
 - recall bias, 102
 - selection bias, 161
 - statin use, 219
- colorectal cancer, and aspirin, 238
- common-source outbreaks, 293
- communicable diseases, *see* infectious diseases
- communication of risk, 291
- community trials, 99
- competing causes, 36
- complex systems, 362–3
- component causes, 230, 232
- conditional logistic regression, 202
- confidence intervals
 - described, 148–50
 - formulae, 377–8
 - and *p*-values, 150–1, 153
- confidentiality, 87
- confounders
 - characteristics of, 189–90
 - determining, 192–5
- confounding, 24
 - and associations, 192, 194
 - and case-control studies, 187–9
 - checking for in reports, 217–20
 - and cohort studies, 192
 - control by data analysis, 200–6
 - controlling by matching, 198–200
 - controlling by randomisation, 197
 - controlling by restriction, 197
 - controlling by stratification, 200–2
 - definition, 186
 - effects of, 190–2
 - by indication, 197, 219
- multivariable modelling, 202–4
 - and population attributable fractions (PAF), 134
- residual, 204
- and size of studies, 200
- and study design, 195–200
- versus effect modification, 201
- consistency, in evaluating causation, 238, 256
- contamination, 99
- continuous measures, 139, 173
- contraception, oral
 - benefits versus harm, 308
 - and coronary heart disease (CHD), 192–4
 - and ovarian cancer, 125–6
 - and thromboembolism, 166
- control event rate (CER), 40, 129
- control groups
 - hospital controls, 108–9
 - population controls, 108
 - selection, 106, 108, 166
- convenience samples, 77
- coronary angiography, and pressure bandages, 128–9, 132
- coronary heart disease (CHD)
 - British Doctors Study, 138–9
 - and contraception, oral, 192–4
 - disease registries, 76
 - see also* ischaemic heart disease (IHD)
- correlation studies, *see* ecological studies
- counterfactual approach, 95
- counterfactual (potential) outcomes model of causation, 236–7
- Cox proportional hazards regression, 202
- Creutzfeldt-Jakob disease (CJD), and blood transfusion, 214
- critical appraisal, 211
- critical point in disease process, 327
- cross-level bias, 41
- cross-sectional studies, 110–12
 - bias in, 162
 - definition, 36, 81
 - depression risk factors, 218
 - odds ratios, 128
 - reverse causality, 111
 - selection bias, 111
- crossover trials, 95, 98
- crude rates, 42–3, 366
- cumulative incidence, *see* incidence proportion (IP)
- data
 - big, 86–7
 - experimental, 241
 - surveillance, 276
 - synthesis, 360
 - variety, 87
 - velocity, 87
 - veracity, 86
 - volume of, 86
 - see also* health data

- data linkage, 104–5, 168
- death
 - competing causes, 36
 - establishing cause of, 72, 73, 75
 - see also* mortality rates
- death registers, 71, 73
- Declaration of Helsinki, 114
- deduction, 235
- demographic and health surveys, 68, 81
- demographic surveillance systems, 68, 72
- denominators, 32
- density sampling, 127
- depression risk factors, 217
- descriptive epidemiology, 7, 35, 66, 359
- descriptive statistics, 16
- descriptive studies
 - assessing, 223
 - by person, place and time, 7, 17–21, 292
 - selection bias, 161
- detection bias, 166
- diabetes
 - and body mass index (BMI), 239–40, 313
 - in China, 80
 - gestational, 29
 - and obesity, 140–1
 - trends in mortality, 74
- diagnostic studies, 112
- diagnostic tests
 - accuracy, 336
 - compared to screening tests, 335
 - predictive values, 336
 - sensitivity, 336–9
 - specificity, 336–9
- diethylstilboestrol (DES) exposure, and vaginal cancer, 151
- difference measures, 129–38
- differential misclassification, 175–6, 181, 215, 216
- digital surveillance, 271–3
- direct standardisation, 45, 50, 366–7
- direct transmission, 289
- directed acyclic graphs (DAGs), 190, 191, 195–6
- disability-adjusted life years (DALYs), 2, 58–9, 232, 233
- disability-free life expectancy, 55–6
- disease
 - attributable and avoidable burden, 314–16
 - burden of, 135, 267, 305, 314–16
 - control, 303, 305
 - diagnosis, 28, 326, 329
 - duration of, 34–5
 - elimination of, 268
 - endemic, 286
 - measures of, 28–30
 - natural history of, 16, 326
 - notifiable, 41, 76
 - process, 326–7
 - prognosis, 16
 - and screening, 328–9
 - see also* incidence; prevalence (P); prevention
- disease registries, 68, 75–6
- Doll, Sir Richard, 14, 21
- dose-response relationships, 239–40
- dynamic simulation modelling, 362
- Ebola virus outbreak, 266, 267, 291
- eco-epidemiology, 4
- ecological fallacy, 41, 86
- ecological studies, 54, 85–6, 113
- effect measures, *see* measures of association
- effect modification, 201
- electronic medical records, 76
- eligibility criteria, 167
- endemic diseases, 286
- endocarditis, and aspirin, 40, 124
- epidemic curves, 13, 293, 294
- Epidemic Intelligence Service (EIS), 291
- epidemics
 - definition, 6–8, 284, 286
 - point- or common-source, 293–4
 - propagative, 293
 - see also* outbreaks
- epidemiology
 - definition, 2–3
 - dimensions of, 16–21
 - historical beginnings, 10–15
 - purposes, 15–16
 - role of, 2
 - subdisciplines, 4–6
- errors
 - assessing effects of, 179–81
 - control of, 178–9
 - limiting, 357
 - random, 171–2, 176, 180
 - random sampling, 146–7, 161, 169
 - sources of, 160–1, 177–8
 - systematic, 161, 172–3, 175
 - type I or alpha (α), 147
 - type II or beta (β), 147, 151–2
 - see also* measurement errors
- Escherichia coli* infection, 283
- ethics, 113–15, 152
- event-based surveillance, 268–9, 271–2
- event rates, 129. *see also* incidence proportion (IP)
- evidence classification, 249, 256
- excess rates, 130
- excess risks, 130
- exchangeability, 121, 131
- exchangeable groups, 95, 96
- exclusion criteria, 167
- expected years of life lost (EYLL), 56
- experimental data, in evaluating causation, 241
- experimental event rate (EER), 40, 129
- external comparisons, to assess selection bias, 169
- external validity, 162, 222 *see also* generalisability
- false negative test results, 330
- false positive test results, 330
- Farr, William, 11, 66, 233
- fetal death rates, 51, 52
- fetal death ratios, 51, 52
- flea treatment, and autism spectrum disorders, 217
- fluoridation, 99
- follow-up studies, *see* cohort studies
- fomites, 289
- food frequency questionnaires, 174–5, 179
- force of morbidity, 38
- forest plots, 250
- Framingham Heart Study, 101–2
- funnel plots, 248
- Gapminder World, 81
- generalisability (external validity), 103, 112, 162, 222
- gestational diabetes, 29
- Global Cancer Observatory, 81
- global health indicators, 51–61
- Global Health Observatory, 81
- glossary, 381–92
- Goldberger, Joseph, 14
- GRADE (Grading of Recommendations, Assessment, Development and Evaluation) criteria, 256
- Graham, Evart, 14
- Graunt, John, 11
- H1N1 influenza virus, 284
- H5N1 avian influenza, 271
- haemolytic uraemic syndrome, 283
- harm from screening programs, 348, 349
- hazard ratios, 198, 202
- head injury, and bicycle helmets, 137, 207
- health-adjusted life expectancy (HALE), 2, 57–8
- health data
 - morbidity, 68, 75–87
 - mortality, 68–72
 - record linkage, 104–5, 168
 - use of existing, 81–6
- health and demographic surveillance systems (HDSS), 68, 72
- health expectancy measures, 56
- health gap measures, 56
- health records, 68, 76–7, 104
- healthcare recorders, 268
- HealthMap, 273
- healthy worker effect, 163
- heart disease, and energy intake, 191, 192, 194, 196

- Helicobacter pylori*, and stomach cancer, 85–6, 113, 212, 240, 241–2
- hepatitis A, and tomatoes, 296
- hepatitis rates, 34
- heterogeneity, assessing, 250–1
- Hill, Sir Austin Bradford, 14, 21, 236, 240
- Hippocrates of Cos, 10, 113
- historical cohort studies, 5, 102
- HIV/AIDS
- prevalence and incidence rates, 30–3
 - screening for, example, 332–5
- hospital administrative systems, 68, 76, 77
- hospital controls, 108–9
- hosts of infection, 288
- human papillomavirus (HPV) infection, 360
- human research ethics guidelines, 114
- Hume, David, 235
- hypothesis tests, 147, 148, 153, 154
- inception cohort, 105
- incidence, 33
- estimating, 126
 - and prevalence, 30–3
 - standardised, 45–6
 - and treatments, 35
- incidence density, *see* incidence rates (IR)
- incidence proportion (IP)
- calculation, 36, 39–40, 61, 129
 - in clinical epidemiology, 129
 - in clinical trials, 40
 - and incidence rates, 37, 38
 - and lifetime risk, 47
 - versus incidence rate, 38
- incidence rates (IR), 41
- age-specific, 43–4
 - calculation, 34, 37, 42, 61
 - crude, 42–3
 - estimating, 135
 - formulae for standard deviation, 378
 - and incidence proportion (IP), 37, 38
 - and prevalence, 34–5
- incident cases, 33
- incubation periods, 288
- indicator-based surveillance, 268, 270
- Indigenous Australians, mortality rates, 17–18
- indirect standardisation, 48, 50, 372–3
- indirect transmission, 289
- individual risk, versus population risk, 308–11
- induction, in causation, 235
- induction period, 327
- infant mortality rates, 51, 53, 54
- infection, 287
- infectious agents, 287–8
- hosts, 288
 - transmission, 288–9
- infectious disease epidemiology, 4, 285
- infectious diseases
- causal model, 287
 - challenges of, 286
 - definition, 285
 - distribution, 283
 - and environmental factors, 290
 - and epidemiology, 285–6
 - zoonotic origins, 286
 - see also* outbreaks
- infectivity, 287
- infestation, 287
- influenza immunisation rates, 131
- telephoning patients, 124–5,
- 131
- influenza vaccination, and narcolepsy in children, 274
- informants, key, 202
- information bias, *see* measurement bias
- information errors, 171–3
- see also* misclassification
- injury epidemiology, 4
- injury risk, and child socioeconomic status (SES), 162
- Institute for Health Metrics and Evaluation (IHME), 81
- instrumental variables (IV), 205
- intensity of infections, 287
- intention to treat analysis, 197, 342
- interaction, *see* effect modification
- intermediaries, 189
- internal validity, 162, 212–13, 220–1
- International Agency for Research on Cancer (IARC), 259–60
- International Classification of Diseases, 70, 75
- International Health Regulations (WHO), 271, 291
- International Network for the Demographic Evaluation of Populations and their Health (INDEPTH), 72
- International Studies of Infarct Survival, 96
- interval case, 345
- intervention studies, 21, 95–100, 162, 166
- interventions
- evaluating preventive, 319
 - evaluation, 16
 - preventive, 316–18
 - and surveillance, 267
- interviewer bias, 110, 178
- ischaemic heart disease (IHD)
- age-specific mortality rates, 43
 - age-standardised rates, 45
 - and cholesterol levels, 310
 - crude mortality rates, 42, 43, 45
 - lifetime risk, 370–1
 - mortality rates, 19
 - and sexual activity, 110
- standardised mortality rates, 366–7
- standardised mortality ratio (SMR), 372–3
- and streptokinase, 153
- terms used, 45
- see also* cardiovascular disease (CVD)
- kidney disease, and phenacetin, 107
- Koch, Robert, 285
- Koch's postulates, 285
- laryngitis, and antibiotics, 246
- latent periods, 288, 327
- lead time, 329, 341, 343
- lead-time bias, 343, 344
- Legionnaires' disease, 290
- length bias, 345
- life expectancy, 54–5, 374
- life table, 11, 55, 56, 374
- lifecourse epidemiology, 6, 94, 362
- lifetime risk, 47, 370–1
- likelihood ratio (LR) test, 339
- LILACS database, 247
- Lind, James, 93
- listeria, 289
- literature
- appraising, 249–50
 - searches, 247–8
- logarithmic scale, 20, 251
- longitudinal studies, *see* cohort studies
- loss to follow-up, 41, 97, 103, 162, 166, 170
- Louis, Pierre Charles-Alexandre (1787–1872), 11
- low response rates, 163–5
- lung cancer
- age-standardised rates, 82–3
 - and alcohol, 187–9, 190
 - British Doctors Study, 15, 21, 102, 103, 138–9
 - control of, 305–6
 - lifetime risk, 47
 - mortality rates, 6, 83, 316
 - and smoking, 15, 21
- mammographic screening, 261, 330, 341–2, 343, 348
- Mantel-Haenszel method for calculating pooled odds ratios, 379–80
- mass gathering surveillance, 273
- matched odds ratios, 199
- matching, 198–200
- maternal mortality ratios, 51
- measurement bias, 97, 171, 181, 215–17
- measurement errors, 171–3
- assessment of, 179–81
 - case-control studies, 181
 - checking for in reports, 215–17
 - control of, 178–9

- effects of, 173–7
- overview, 180
- reducing, 358–9
- sources of, 177–8
- see also* misclassification
- measures of association
 - difference measures, 129–38
 - ratio measures, 123–9
- measures of disease, 28–30
 - in practice, 35–41
 - summary of, 61
 - using routine data, 41–7
 - see also* incidence; prevalence (P)
- mediation analysis, 190
- MEDLINE database, 247
- Mendel, Gregor, 206
- Mendelian randomisation (MR), 206
- menopausal hormone therapy trial, 219
- mesothelioma, 270
- meta-analysis, 153, 252–3, 380
- migrant studies, 84–5
- Millennium Development Goals, 51, 52
- Million Death Study, India, 72
- misclassification, 102, 171
 - and bias, 173
 - differential, 175–6, 181, 215, 216
 - non-differential, 173–5, 181, 215, 217
- mobile telephones
 - and brain cancer, 254–5
 - using for surveillance, 277
- molecular epidemiology, 5
- moral principles, 113
- morbidity, force of, 38
- morbidity data, 75–87
- mortality, measures of, 41
- mortality data, 68–72
 - challenges in using, 73–5
 - using, 42
- mortality indicators, 51–4
- mortality rates
 - and age-specific incidence, 43–4
 - age-standardised rates, 45–6
 - all-cause, 7, 42, 46–7
 - cardiovascular disease (CVD), 319
 - crude, 366
 - and crude incidence, 42–3
 - Indigenous Australians, 17–18
 - ischaemic heart disease (IHD), 42, 43, 45
 - lung cancer, 6, 83, 316
 - by person, place and time, 17–21
 - Russians, 7
 - standardised, 366–7
 - and standardised incidence, 45–6
 - trends in United States, 19–20, 74
 - tuberculosis (TB), 303–4
 - and veterans' health, 164
- mortality ratios
 - proportional, 50, 61
 - and standardised incidence, 48, 129
- multiple logistic regression, 202
- multivariable modelling, 202–4
- n*-of-1 trials, 98
- narcolepsy in children, and influenza vaccination, 274
- narrative reviews, 245
- National Health and Nutrition Examination Surveys (NHANES), 79, 110
- natural history of disease, 16
- necessary causes, 198, 230
- negative predictive values (NPV), 331–2
- negative test results, true and false, 330
- neonatal mortality rates, 51
- nested case–control studies, 105, 106
- non-communicable disease
 - reporting, 270
- non-differential misclassification, 173–5, 181, 215, 217
- non-infectious diseases, clusters, 296–9
- non-maleficence, 113
- non-randomised designs, 99, 346–8
- non-responders, 165
- notifiable disease systems, 68, 269
- notifiable diseases, 41, 76
- null hypothesis, 147
- null values, 150
- number needed to treat (NNT), 132
- numerators, 32
- Nuremberg Code, 113, 114, 115
- Nurses' Health Study (US), 21, 102
- nutritional epidemiology, 4, 355
- obesity, and type-2 diabetes, 140–1
- observational studies, 100–13, 206, 212
- observer bias, 110, 178
- occupational epidemiology, 5
- occupational studies, 50
- odds, 126
- odds ratios (OR)
 - approximating rate ratios, 127
 - approximating risk ratios, 127, 376
 - calculation, 125–7
 - case–control studies, 126–7
 - cross-sectional studies, 128
 - interpreting, 127
 - matched, 199
 - pooled, 188, 379
 - using 2×2 tables, 188
- oesophageal adenocarcinoma, and smoking, 214–15
- outbreaks
 - common-source, 293
 - confirmation phase, 295
 - definition, 284
 - evidence of causation, 295–6
 - hypothesis–generation and testing phase, 294–5
 - identification phase, 292–4
 - investigating steps, 291–2
 - management, 290–1
 - non-infectious diseases, 296–9
 - point-source, 293
 - propagative, 293
 - role of epidemiology, 284
 - and surveillance, 267
 - see also* clusters
- ovarian cancer, and oral contraceptive pill, 125–6
- p*-values, 147
 - and confidence intervals, 150–1, 153
 - interpreting, 152–5
 - reliance on, 154
 - and statistical significance, 152, 154
- pandemics, 284
- parallel group trials, 98
- participants, 102, 106, 162–3
 - see also* selection bias
- passive surveillance, 268
- pathogenicity, 287
- pellagra, 14
- per protocol analysis, 197
- percentages, 32
- perinatal epidemiology, 4
- period prevalence, 32
- person–time measures, 37
- person-years, 37
- pharmaceutical drugs, 268
- pharmacoepidemiology, 108, 109
- phenacetin, and kidney disease, 107
- phenylketonuria, screening for, 328
- philosophy, 235–6
- Physicians' Health Study (US), 96
- PICO (Participants, Interventions, Comparisons and Outcomes), 247
- placebo, 97
- placebo effect, 97
- placebo groups, *see* control groups
- plausibility, in evaluation of causation, 240
- point estimates, 148
- point prevalence, 32
- point-source outbreaks, 293
- polio eradication, 277
- poliomyelitis vaccine trial, 96, 224–5
- pooled analysis, 253
- pooled odds ratios, 188, 379
- Popper, Karl, 235
- population attributable fractions (PAF), 134–5, 136–7, 314
- population attributable risk percent, *see* population attributable fractions (PAF)
- population attributable risks (PAR), 133–4
 - interpreting, 135
 - strengths and uses, 139
- population risk, versus individual risk, 308–11

- populations
 - at risk, 34, 39
 - defining, 166
 - standard, 46, 50, 368
 - stationary, 35
 - study, 50, 77
 - target, 77
 - whole, 133
- positive predictive values (PPV), 331–2, 340
- positive test results, true and false, 330
- post-test probability, 336
- potential impact fraction (PIF), 315
- potential years of life lost (PYLL), 56–7
- power of studies, 146, 151–2
- precision
 - assessing, 179
 - and confidence intervals, 148
 - poor, 171, 172
- predictive values
 - diagnostic tests, 336
 - positive and negative, 331–2, 340
- pressure bandages, and coronary angiography, 128–9, 132
- pre-test probability, 336
- prevalence (P)
 - calculation, 33, 34, 39, 61
 - definition, 32
 - and incidence, 30–3
 - and incidence rates, 30, 34
- prevalence odds ratios (POR), 128
- prevalence ratios, 123, 125
- prevalence surveys, 77
- prevalent cases, 108, 112
- prevention
 - choosing strategy, 306
 - definition, 303
 - and epidemiology, 303, 305–7
 - evaluating interventions, 319
 - high-risk strategy, 311–12
 - interventions, 316–18
 - mass strategy, 312–13
 - ‘middle-road’ strategy, 313
 - paradox, 320
 - and population attributable fractions (PAF), 314
 - population or individual level, 308–11
 - primary, 16, 303, 304
 - primordial, 304
 - scope of, 307–8
 - secondary, 303, 325
 - tertiary, 303
- preventive trials, 95, 97
- primary prevention, 16, 303, 304
- primordial prevention, 304
- privacy laws, 114
- probability values, *see p-values*
- prognosis of disease, 16
- prognostic studies, 105
- Program for Monitoring Emerging Diseases (ProMED), 271
- propagative outbreaks, 293
- propensity scores, 205
- proportional mortality ratios (PMR), 50, 61
- proportions, 48
- prospective studies, *see cohort studies*
- PROSPERO register, 247
- prostate cancer, screening for, 328
- public health
 - factors determining, 270
 - goals, 28
 - policy, 260–1
- Public Health Emergency of International Concern (PHEIC), 271
- public health epidemiology, 4
- publication bias, 248
- PubMed® database, 247
- quality-adjusted life year (QALY), 57
- quantitative bias analysis, 171, 180
- random errors, 171–2, 176, 180
- random sampling errors, 146–7, 161, 169
- random selection, 96
- randomisation, 96, 197, 206
- randomised controlled trials (RCTs)
 - compared to cohort studies, 101
 - follow-up, 97
 - interpreting results, 219
 - and interventions, 197
 - and screening programs, 346
 - selection bias, 98
 - study design, 95–8
 - translation of results, 319
- rare disease assumption, 128
- rate of change, 305
- rate differences, 130–1
 - see also* attributable risks (AR)
- rate ratios, 123, 127
- rates, 48
- ratio measures, 123–9
- ratios, 48
- reading reports
 - assessing descriptive studies, 223
 - checking for confounding, 217–20
 - checking for measurement bias, 215–17
 - checking role of chance, 220
 - checking for selection bias, 213
 - identifying research question, 212
 - internal validity, 212–13, 220–1
 - interpreting results, 219, 221–2
 - questions to consider, 211, 215, 217
 - study designs, 212
 - systematic approach, 211
 - see also* systematic reviews
- recall bias, 102, 110, 175, 177
- receiver operating characteristic (ROC) curves, 339
- record linkage, 104–5, 168
- recorders, 268
- recruitment of participants, *see selection bias*
- reference groups, *see control groups*
- reference rates, 130
- reference tests, 112
- regression analysis, 202
- relative measures, 123–9
- relative risk increase (RRI), 124, 129
- relative risk reduction (RRR), 129
- relative risks, 4
 - in clinical epidemiology, 128–9
 - and confidence intervals, 150
 - and null value, 150
 - strengths and uses, 139
 - use of term, 128
 - versus attributable risks, 138–9
 - see also* risk ratios
- relative survival rates, 50
- reports
 - guidelines for results, 224
 - see also* reading reports
- research
 - ethics, 114, 152
 - translation into practice, 354–62
- research questions, 212, 247
- reservoirs of infection, 287
- residual confounding, 204
- response rates, low, 165
- restriction, to control confounding, 197
- results
 - graphing, 250
 - guidelines for reporting, 224
 - interpreting in reports, 221–2
 - translation to real world, 319
- retrospective cohort study, *see historical cohort studies*
- reverse causality, 21, 102, 111
- risk
 - formulae for standard deviation, 378
 - lifetime, 47, 370–1
 - outbreak assessment tools, 291
 - population versus individual, 308–11
 - populations at, 34, 39
 - see also* incidence proportion (IP)
- risk differences, 130, 131
- risk factors, 19, 59, 101
- risk ratios, 123–5
 - odds ratio as approximate, 127, 376
- rounding, 33, 126
- rumour surveillance, 271
- sample size, 151
- sampling, 78
- sampling error (random), 146–7
 - see also* chance; sample size
- SARS epidemic (2003), 50, 271, 286
- screening, 325–50
 - aims of, 325–6
 - for bowel cancer, 329, 347
 - for breast cancer, 261, 330, 341–2, 343, 348

- for cervical cancer, 346–7
- critical point, 327
- definition of, 325
- and disease, 328–9
- and epidemiology, 326
- for HIV, 332–5
- negative consequences, , 348–9
- for phenylketonuria, 328
- for prostate cancer, 328
- relationship to the disease process, 326–7
- versus case-finding, 327
- see also* screening programs; screening tests
- screening programs
 - disease suitability, 328–9
 - evaluating, 340–1
 - lead-time bias, 343, 344
 - length bias, 345
 - negative consequences, 348–9
 - potential sources of bias in evaluation, 341–5
 - requirements, 328–36, 338
 - study designs for evaluation, 345–8
 - test requirements, 329–30
 - volunteer bias, 341–2
- screening tests
 - accuracy, 329
 - compared to diagnostic tests, 335
 - negative predictive values, 331–2
 - positive predictive values, 331–2, 340
 - requirements, 329–30
 - sensitivity, 329, 330–1
 - specificity, 329, 330–1
 - true and false negatives, 330
 - true and false positives, 330
- curvy, 93
- secondary attack rate, 287
- secondary prevention, 303, 325
 - see also* screening
- selection bias (systematic sampling error)
 - assessing effects of, 168–71
 - case-control studies, 161, 169
 - checking for in reports, 213
 - clinical trials, 162, 166
 - cohort studies, 161
 - control of, 166–8
 - cross-sectional studies, 111
 - definition, 161
 - descriptive studies, 161
 - evaluation of screening programs, 341–3
 - healthy worker effect, 163
 - and loss to follow-up, 162, 166
 - low response rates, 163–4
 - and random sampling errors, 146
 - randomised controlled trials (RCTs), 98
 - sources of, 162–6
 - sensitivity analysis for, 170
 - volunteer bias, 162–3
- self-controlled case series, *see* case-crossover studies
- sensitivity, of screening tests, 174, 329, 330–1, 336–8
- sensitivity analysis, 170, 180, 213, 217
- sentinel surveillance, 273
- sexual activity, and myocardial infarction (heart attack), 110
- shoe-leather epidemiology, 20
- significance, *see* statistical significance
- Simpson's paradox, 186, 190
- smallpox, 20
- smoking
 - and asthma, 32
 - and lung cancer, 14–15, 83, 138–9, 188, 190, 204, 233, 305–6, 316
 - and oesophageal adenocarcinoma, 214–15
 - response rates, 165
 - and stroke incidence, 121–2, 130, 132, 133, 135
- Snow, John, 12–14, 22–4
- social epidemiology, 4, 94
- socioeconomic status (SES), and child risk of injury, 162
- specificity
 - as factor in evaluating causality, 240–1
 - of screening tests, 174, 329, 330–1, 336–8
- standard populations, 46, 368
- standardisation
 - direct, 45, 50, 366–7
 - indirect, 48, 50, 372–3
- standardised incidence ratios (SIR), 48, 50, 61, 372–3
- standardised mortality ratios (SMR), 18, 48, 50, 61, 84, 372–3
- statin use, and atrial fibrillation, 219
- stationary populations, 35
- statistical significance, 147–8, 152, 154, 155–6
- stepped-wedge design, 99
- stillbirth rates, 51, 52
- stillbirth ratios, 52
- stomach cancer, and *Helicobacter pylori*, 85–6, 113, 212, 240, 241–2
- stratification, to identity and control confounding, 188, 200–2
- streptokinase, and heart attack mortality, 153
- stroke incidence, and smoking, 121–2, 130, 132, 133, 135
- study designs
 - case-control studies, 106–10, 168
 - case-crossover studies, 110
 - cohort studies, 100–3
 - control of confounding, 195–200
 - cross-sectional studies, 110–12
 - eligibility and exclusion criteria, 167
 - ideal, 94–5, 212
 - instrument choice, 178–9
 - intervention studies, 95–100
 - observational studies, 100–13
 - randomised controlled trials (RCTs), 95–8
 - screening program evaluation, 345–8
 - study populations, 50, 77
 - sudden infant death syndrome (SIDS) study, 107
 - sufficient causes, 230
 - suicide rates, 61, 111, 112, 203, 317–18
 - surveillance
 - active, 268
 - case definition, 276
 - definition, 267
 - digital, 271–3
 - and epidemiology, 266
 - essentials, 275
 - event-based, 268–9, 271–2
 - indicator-based, 268, 270
 - key steps, 267
 - mass gathering, 273
 - passive, 268
 - rumour, 271
 - sentinel, 273
 - syndromic, 276
 - types of, 268–74
 - undercount, 275–6
 - using mobile telephones, 277
 - surveillance data
 - analysis, 276–8
 - collection, 276, 277
 - surveillance pyramid, 275
 - surveillance systems, 278
 - surveys, 77, 79
 - see also* cross-sectional studies
 - survival curves, 55
 - survival rates, 50
 - survival studies, 105
 - Sustainable Development Goals, 16, 51, 52, 76
 - syndromic surveillance, 276
 - system science approach, 362, 363
 - systematic errors, 161, 172–3, 174–7
 - systematic reviews, 245–56
 - appraising literature, 249–50
 - assessing heterogeneity, 250–1
 - assessing quality of, 256
 - and bias, 254–5
 - conclusions, 256
 - graphical display of results, 250
 - guidelines for, 245–6, 257
 - literature searches, 247–8
 - meta-analysis, 252–3
 - pooled analysis, 253
 - PROSPERO register, 247
 - publication bias, 248
 - summarising the data, 250–6
 - specifying research question, 247
 - studies for inclusion, 248, 253
 - validity of, 257
 - writing, 246

- tables, 2×2, 124
- target populations, 77, 78, 166, 169
- telephoning patients, influenza immunisation rates, 124–5, 131
- temporality, as factor in evaluating causality, 238
- tertiary prevention, 303
- Thai Cohort Study, 102
- thalidomide, and birth defects, 107, 297
- thromboembolism, and oral contraception, 166
- Titanic Inquiry Project, 10, 202
- tomatoes, and hepatitis A, 296
- translation of research into practice, 354–5
 - challenges, 356
 - improving measurement, 358–9
 - limiting error, 357
 - phases, 354
 - synthesis and integration, 360–2
- transmission of infection, 288–9
- true negative test results, 330
- true positive test results, 330
- tuberculosis (TB), mortality rates, 303–4
- Tuskegee syphilis study, 114
- type I errors, 147, 151
- type II errors, 147, 151–3
- type-2 diabetes
 - and body mass index (BMI), 239–40
 - and obesity, 140–1
- typhoid, 288
- under-5 mortality rates, 51
- undercount, 275–6
- United Nations, 291
- United States
 - all-cause mortality rates, 46–7
 - trends in mortality rates, 19–20, 74
- US Air Force Suicide Prevention Program, 317–18
- US Community Guide, 259
- US Physicians’ Health Study, 96
- US Preventive Services Task Force (USPSTF), 250, 258–62, 328, 346
- vaginal cancer, and diethylstilboestrol (DES) exposure, 151, 260, 297
- validity
 - external, 162, 222
 - internal, 162, 212–13, 220–1
 - of systematic review, 257
- verbal autopsies, 72
- veterans’ health, and mortality rates, 164
- virulence, 287
- vital statistics, 68–72
- vitamin A, and childhood mortality, 96
- volunteer bias, 162–3, 341–2
- Women’s Health Initiative (WHI), 219
- World Cancer Research Fund, 260, 319
- World Health Organization (WHO), 2, 46, 51, 56, 76, 266, 271, 277, 289, 291, 314
 - Global Cancer Observatory, 81
 - Global Health Observatory, 81, 83
 - International Classification of Diseases, 70, 75
- writing papers, 223–4
- Wynder, Ernest, 14
- years of life lost (YLL), 56–7
- zoonotic origins of infections, 286